title: Author reply: To PMID 23084240.
authors.affiliation: Ophthalmic Consultants of Boston and Tufts University School of Medicine, Boston, Massachusetts.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Heier
authors.affiliation: Retina Consultants of Houston, Houston, Texas.
authors.forename: David M
authors.initials: DM
authors.lastname: Brown
authors.affiliation: Oxford Eye Hospital, University of Oxford, Oxford, United Kingdom.
authors.forename: Victor
authors.initials: V
authors.lastname: Chong
authors.affiliation: CHU de Bordeaux - Université Bordeaux 2, Bordeaux, France.
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Korobelnik
authors.affiliation: Cole Eye Institute, Cleveland, Ohio.
authors.forename: Peter K
authors.initials: PK
authors.lastname: Kaiser
authors.affiliation: Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska.
authors.forename: Quan Dong
authors.initials: QD
authors.lastname: Nguyen
authors.affiliation: University of Cologne, Cologne, Germany.
authors.forename: Bernd
authors.initials: B
authors.lastname: Kirchhof
authors.affiliation: Wills Eye Hospital, Philadelphia, Pennsylvania.
authors.forename: Allen
authors.initials: A
authors.lastname: Ho
authors.affiliation: Nagoya City University, Nagoya, Japan.
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Ogura
authors.affiliation: Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.
authors.forename: Ursula
authors.initials: U
authors.lastname: Schmidt-Erfurth
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D011993:Recombinant Fusion Proteins